Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - bendamustine hydrochloride - pdr/conc/soln for infus - 100 milligram - bendamustine

Malta - Inggris - Medicines Authority

fresenius kabi oncology plc - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 2.5 mg/ml - antineoplastic agents

Malta - Inggris - Medicines Authority

fresenius kabi oncology plc - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 2.5 mg/ml - antineoplastic agents

Israel - Inggris - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - Inggris - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - Inggris - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - Inggris - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine

Amerika Serikat - Inggris - NLM (National Library of Medicine)

eagle pharmaceuticals, inc - bendamustine hydrochloride (unii: 981y8sx18m) (bendamustine - unii:9266d9p3pq) - bendamustine hydrochloride injection is indicated for the treatment of patients with chronic lymphocytic leukemia. efficacy relative to first line therapies other than chlorambucil has not been established. bendamustine hydrochloride injection is indicated for the treatment of patients with indolent b-cell non-hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. bendamustine hydrochloride injection is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol. [see warnings and precautions (5.3)] pregnancy category d [see warnings and precautions (5.9)] risk summary bendamustine hydrochloride can cause fetal harm when administered to a pregnant woman. bendamustine caused malformations in animals, when a single dose was administered to pregnant animals. advise women to avoid becoming pregnant while receiving be